Adaptive Biotechnologies (NASDAQ:ADPT) Stock: Insider Julie Rubinstein Sells 11,881 Shares

Posted by Grant Hamersma on Nov 3rd, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 11,881 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $25.47, for a total value of $302,609.07. Following the completion of the sale, the chief operating officer owned 377,802 shares of the company’s stock, valued at $9,622,616.94. The trade was a 3.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

On Friday, October 30th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.73, for a total value of $317,579.13.
On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.45, for a total value of $338,014.45.
On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.04, for a total value of $309,381.24.
On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.98, for a total value of $296,787.38.
On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.05, for a total value of $285,738.05.
On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total value of $301,896.21.
On Thursday, October 15th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.61, for a total value of $304,272.41.
On Tuesday, October 13th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.50, for a total value of $302,965.50.
On Thursday, October 8th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.66, for a total value of $304,866.46.
On Monday, October 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $29.19, for a total value of $346,806.39.

Adaptive Biotechnologies Price Performance

ADPT traded up $0.74 during trading on Tuesday, reaching $25.80. 1,494,257 shares of the company traded hands, compared to its average volume of 2,050,401. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. Adaptive Biotechnologies Corporation has a 12-month low of $12.00 and a 12-month high of $30.74. The firm has a fifty day simple moving average of $26.37 and a 200 day simple moving average of $19.71. The company has a market cap of $4.12 billion, a P/E ratio of -62.93 and a beta of 2.18.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Ethic Inc. bought a new stake in Adaptive Biotechnologies in the third quarter worth $244,000. Pictet Asset Management Holding SA raised its stake in Adaptive Biotechnologies by 12.5% during the third quarter. Pictet Asset Management Holding SA now owns 17,924 shares of the company’s stock valued at $518,000 after purchasing an additional 1,985 shares in the last quarter. Parr Mcknight Wealth Management Group LLC bought a new position in Adaptive Biotechnologies during the third quarter valued at $217,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Adaptive Biotechnologies during the third quarter valued at $236,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Adaptive Biotechnologies by 14.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 29,120 shares of the company’s stock valued at $838,000 after purchasing an additional 3,649 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ADPT. Piper Sandler upped their target price on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Morgan Stanley lifted their price target on shares of Adaptive Biotechnologies from $22.00 to $27.00 and gave the company an “equal weight” rating in a report on Monday, October 12th. TD Cowen boosted their price target on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Guggenheim increased their price objective on shares of Adaptive Biotechnologies from $25.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Finally, BTIG Research raised their price objective on Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Tuesday, September 22nd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $30.06.

Get Our Latest Research Report on ADPT

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.